Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

BACKGROUND: The potential for PPAR agonists to positively affect risk of cardiovascular disease in patients with type 2 diabetes (T2DM) is of persistent attention. The PRESS XII study primarily aimed to evaluate the efficacy and safety of saroglitazar (2 mg and 4 mg) as compared to pioglitazone 30 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnappa, Manjunath, Patil, Kishor, Parmar, Krupi, Trivedi, Purav, Mody, Nirali, Shah, Chintan, Faldu, Khushboo, Maroo, Sanjay, Parmar, Deven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305598/
https://www.ncbi.nlm.nih.gov/pubmed/32560724
http://dx.doi.org/10.1186/s12933-020-01073-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305598/
https://www.ncbi.nlm.nih.gov/pubmed/32560724
http://dx.doi.org/10.1186/s12933-020-01073-w

Ejemplares similares